Population Pharmacokinetic and Exposure–dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients

por Cosson, Valérie, Schaedeli‐Stark, Franziska, Arab‐Alameddine, Mona, Chavanne, Clarisse, Guerini, Elena, Derks, Michael, Mallalieu, Navita L.
Publicado 2018

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA(A)-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

por Goeldner, Celia, Kishnani, Priya S., Skotko, Brian G., Casero, Julian Lirio, Hipp, Joerg F., Derks, Michael, Hernandez, Maria-Clemencia, Khwaja, Omar, Lennon-Chrimes, Sian, Noeldeke, Jana, Pellicer, Sabine, Squassante, Lisa, Visootsak, Jeannie, Wandel, Christoph, Fontoura, Paulo, d’Ardhuy, Xavier Liogier
Publicado 2022

Basmisanil, a highly selective GABA(A)-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man

por Hipp, Joerg F., Knoflach, Frederic, Comley, Robert, Ballard, Theresa M., Honer, Michael, Trube, Gerhard, Gasser, Rodolfo, Prinssen, Eric, Wallace, Tanya L., Rothfuss, Andreas, Knust, Henner, Lennon-Chrimes, Sian, Derks, Michael, Bentley, Darren, Squassante, Lisa, Nave, Stephane, Nöldeke, Jana, Wandel, Christoph, Thomas, Andrew W., Hernandez, Maria-Clemencia
Publicado 2021